Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.
Please provide your email address to receive an email when new articles are posted on . “Elevated [IOP] is one of the major risk factors for development and progression of POAG [primary open-angle ...
Zacks Investment Research on MSN
Here's why you should retain Glaukos stock in your portfolio now
Glaukos Corporation GKOS is well-poised for growth on the back of expansion of interventional glaucoma, clinical and ...
Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos ...
Robert Haverly, MD, of Saint Vincent Surgery Center in Erie, Pa., has incorporated the iStent into his practice for glaucoma treatment, according to an Erie Times-News report. The iStent was the ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
Glaukos Corp. (NYSE: GKOS) is seeing its continued efforts to bring new and improved products to the micro-invasive glaucoma surgery (MIGS) market pay off. MIGS-related net sales for the San Clemente ...
CHERRY HILL, N.J. (WPVI) -- A new procedure is helping to preserve vision for some people with glaucoma. Glaucoma is a silent thief, affecting 3 million Americans, slowly robbing them of their sight.
Glaukos Corp. reported 12-month results from the pivotal IDE trial of its Istent Infinite trabecular micro-bypass system, showing substantial reduction in mean diurnal intraocular pressure (IOP) in ...
Glaukos secured a new FDA clearance for its miniaturized stent system designed for glaucoma to help drain the inner eye of built-up fluids and normalize intraocular pressure. The company had received ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
More than two million Americans have glaucoma, but only half know it. Untreated, it can cause blindness. In the past, glaucoma sufferers either had to undergo risky surgery or use daily eye drops to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results